secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001493152-23-026160
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q2 revenue up 32% to $20.2M; raises FY 2023 guidance to $75-77M
-----------------------------------------------------------------------------

- Revenue $20.2M, up 32% YoY (14% organic, 18% from Coflex/CoFix acquisition).
- Gross margin 61.6%, up from 54.8% in Q2 2022, driven by Coflex/CoFix contribution.
- Net loss $2.2M ($0.02/share) vs $1.7M ($0.02) prior; adjusted EBITDA turned positive at $0.1M.
- Raises FY 2023 revenue guidance to $75-77M from $73-75M, representing 29-33% annual growth.
- CEO Sean Browne highlighted strength across channels and positive adjusted EBITDA ahead of expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-026160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer